Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AAM vs GRDN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRDN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

GRDN Overall Winner 6-Pillar Tally: AAM 0 – 6 GRDN Matrix Metrics: AAM 4 – 6 GRDN

As of Nov 20, 2026, Guardian Pharmacy Services, Inc. (GRDN) is the stronger overall head-to-head candidate over AA Mission Acquisition Corp. (AAM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAM carries a Unified Composite Score of 59.9/100 (HOLD) at $10.66 (N/M Forward P/E, 0.0% operating margin), whereas GRDN carries 35.9/100 (SELL) at $46.94 (31.3x Forward P/E, 6.5% operating margin).

  • Composite vs. Pillar Nuance: While AAM currently prints a higher short-term Unified Composite Score (59.9/100 HOLD vs. GRDN 35.9/100 SELL), GRDN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.5% vs. 0.0% operating margin) and revenue trajectory (-1.7% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AAM vs GRDN
AAM NYSE
AA Mission Acquisition Corp.
Blank Checks
$10.66
+0.19% 1D
Market Cap $467.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.01β · 3% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.8 · SMA20: $10.67 · SMA50: $10.64
GRDN NYSE Head-to-Head Winner
Guardian Pharmacy Services, Inc.
Retail-Drug Stores And Proprietary Stores
$46.94
+0.58% 1D
Market Cap $3.0B
TTM Revenue $1.46B
Forward P/E 31.3x
Beta / 30D Vol 0.51β · 56% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 8.0 Fund 35.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.3% over 20 days), RSI 57
RSI-14: 57.2 · SMA20: $44.67 · SMA50: $43.04

6-Pillar Scorecard Institutional Category Breakdown (AAM 0 – 6 GRDN)

Columns: Metric · AAM · GRDN
1. Valuation Multiples GRDN
Forward P/E N/M 31.3x
Trailing P/E N/M 39.9x
PEG Ratio N/M N/M
EV / Revenue N/M 2.0x
2. Growth & Scale GRDN
Revenue Growth (YoY) +0.0% -1.7%
Earnings Growth (YoY) +10.4% +88.8%
TTM Revenue (USD) N/A $1.46B
Market Cap $467.9M $3.0B
3. Profitability & Quality GRDN
Gross Margin N/A 22.4%
Operating Margin 0.0% 6.5%
Net Profit Margin 0.0% 5.1%
Return on Equity (ROE) 411.0% 32.0%
4. Balance Sheet & Cash Flow GRDN
Cash Generation (TTM) N/A $96M
Cash Flow Margin N/A 6.6%
Net Cash / Leverage $8.08 Book/Sh · 411.0% ROE $84M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GRDN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 41.1% (7th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat GRDN
OpEx & R&D Intensity N/A 15.9% of Rev ($232M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Shell Companies Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AAM (4) vs GRDN (6)
Institutional Metric AAM GRDN Criterion Row Edge
Market Capitalization
Scale
$467.9M $3.0B Larger Scale GRDN
Trailing P/E Ratio
Valuation
N/M 39.9x Lower Multiple GRDN
Forward P/E Ratio
Valuation
N/M 31.3x Lower Multiple GRDN
Revenue Growth (YoY)
Growth
+0.0% -1.7% Higher Growth AAM
Operating Margin (TTM)
Profitability
0.0% 6.5% Higher Margin GRDN
Net Profit Margin
Profitability
0.0% 5.1% Higher Margin GRDN
Return on Equity (ROE)
Capital Efficiency
411.0% 32.0% Higher ROE AAM
52-Week Range Position
Momentum
70% ($10–$11) 84% ($26–$51) Stronger Trend GRDN
Beta / 30D Volatility
Risk Regime
0.01β · 3% Vol 0.51β · 56% Vol Lower Realized Risk AAM
Unified Institutional Score
Composite Signal
59.9 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite AAM
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.46B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 22.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.08 Book/Sh · 411.0% ROE) $96M ($84M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRDN +7.67 pp
AAM: -0.09% · GRDN: +7.58%
3M Horizon GRDN +16.55 pp
AAM: +0.95% · GRDN: +17.5%
6M Horizon GRDN +16.55 pp
AAM: +0.95% · GRDN: +17.5%
1Y Horizon GRDN +16.55 pp
AAM: +0.95% · GRDN: +17.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAM vs GRDN. Trailing 12-month operating profitability (AAM 0.0% vs GRDN 6.5%) and valuation multiples (AAM N/M vs GRDN 31.3x Forward P/E) are benchmarked directly in Pillar 4 below.

AAM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E411.0% · N/M
GRDN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.46B
Gross Margin22.4%
Op. Margin6.5%
ROE / Fwd P/E32.0% · 31.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AAM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRDN SURGE
7d in phase · OBV NEUTRAL
Current IV 41.1%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact GRDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AAM Moat Profile High-Margin Pricing Power Moat
Shell Companies Operator
Competes within the Shell Companies value chain with $467.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GRDN Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.0B market capitalization and 6.5% operating margin.
OpEx & R&D Reinvestment 15.9% of Rev ($232M)
90D Engineering Disclosures 0 Published

Investor FAQ AAM vs GRDN Key Questions & Quantitative Answers

As of Nov 20, 2026, Guardian Pharmacy Services, Inc. (GRDN) is the stronger overall head-to-head candidate over AA Mission Acquisition Corp. (AAM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAM carries a Unified Composite Score of 59.9/100 (HOLD) at $10.66 (N/M Forward P/E, 0.0% operating margin), whereas GRDN carries 35.9/100 (SELL) at $46.94 (31.3x Forward P/E, 6.5% operating margin). Composite vs. Pillar Nuance: While AAM currently prints a higher short-term Unified Composite Score (59.9/100 HOLD vs. GRDN 35.9/100 SELL), GRDN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.5% vs. 0.0% operating margin) and revenue trajectory (-1.7% vs. +0.0% YoY).

GRDN leads the Growth & Scale pillar: AAM posts +0.0% YoY revenue growth and +10.4% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GRDN at -1.7% YoY revenue growth and +88.8% YoY earnings growth on $1.46B TTM revenue (22.4% gross margin, 6.5% operating margin). On trailing 12-month operating scale, AAM generates N/A in USD-normalized revenue versus $1.46B for GRDN. In operating R&D and SG&A reinvestment, AAM deploys N/A (0 90-day corporate R&D disclosures) versus 15.9% of Rev ($232M) (0 disclosures) for GRDN.

GRDN screens cheaper on headline valuation multiples. AAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GRDN trades at 31.3x Forward P/E, 39.9x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (6.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAM (411.0% ROE) versus GRDN (32.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AAM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 3% Vol realized risk). By comparison, GRDN carries 41.1% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.51β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.